Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Biomolecules and Biomedicine, [S. l.], v. 22, n. 2, p. 300–301, 2022. DOI: 10.17305/bjbms.2021.6419. Disponível em: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6419.. Acesso em: 22 apr. 2024.